Land: Kanada
Sprache: Englisch
Quelle: Health Canada
ANCESTIM; WATER
BIOVITRUM AB (PUBL)
L03AA12
ANCESTIM
2500MCG; 5ML
KIT
ANCESTIM 2500MCG; WATER 5ML
SUBCUTANEOUS
100
Prescription
HEMATOPOIETIC AGENTS
Active ingredient group (AIG) number: 0237442004; AHFS:
CANCELLED PRE MARKET
2017-09-07
PRODUCT MONOGRAPH STEMGEN ® ANCESTIM HEMATOPOIETIC AGENT STERILE, LYOPHILIZED POWDER FOR RECONSTITUTION SUBCUTANEOUS USE ONLY (1875 MCG/VIAL) Manufactured by: Amgen Amgen Inc. One Amgen Center Drive Thousand Oaks, California U.S.A. 91320-1799 Distributed by: Amgen Canada Inc. 6755 Mississauga Road, Suite 400 Mississauga, Ontario L5N 7Y2 Date of Approval: February 13, 2004 MECS #: 04-103170-301 -1- PRODUCT MONOGRAPH STEMGEN ® ANCESTIM STERILE, LYOPHILIZED POWDER FOR RECONSTITUTION SUBCUTANEOUS USE ONLY (1875 MCG/VIAL) THERAPEUTIC CLASSIFICATION HEMATOPOIETIC AGENT CAUTION: STEMGEN ® MAY CAUSE SEVERE OR LIFE-THREATENING SYSTEMIC ALLERGIC REACTIONS (SEE WARNINGS). ACTION AND CLINICAL PHARMACOLOGY GENERAL STEMGEN ® (ancestim) is recombinant-methionyl human stem cell factor (r-metHuSCF), a homologue of endogenous human stem cell factor (SCF), produced by recombinant DNA technology. 1 Hematopoietic growth factors, including SCF, are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation, commitment, and/or functional activation. Receptors for SCF are found on a range of early to more mature hematopoietic progenitor cells, as well as mast cells, melanocytes, and germ cells. Endogenous SCF is a multilineage hematopoietic growth factor which is produced by bone marrow fibroblasts. 2,3 In humans, the serum concentration of soluble SCF averages 3.3 ± 1.1 ng/mL. 2,3 PHARMACOLOGIC EFFECTS OF STEMGEN ® (ANCESTIM) IN COMBINATION WITH NEUPOGEN ® (FILGRASTIM) In phase 1/2 studies involving 367 patients with breast cancer, non-Hodgkin’s lymphoma, and ovarian cancer, STEMGEN ® administration over a dose range of 5 to 25 mcg/kg/day in combination with a fixed dose of NEUPOGEN ® resulted in a dose- dependent increase in circulating peripheral blood progenitor cells (PBPC) compared to NEUPOGEN ® alone. 4 The PBPCs included CD34 + cells, granulocyte macrophage colony-forming units (CFU-GM), and erythroid burst-forming units (BFU-E). For pat Lesen Sie das vollständige Dokument